Drugs / Carrilizumab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05965154 | Aug 2023 → Apr 2025 | head and neck squamous cell carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05919095 | Jun 2023 → Jun 2025 | gallbladder cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05520814 | Aug 2018 → Dec 2023 | nasopharyngeal carcinoma | Sichuan Cancer Hospital and Research Institute | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05886140 | Jun 2023 → Apr 2025 | skin squamous cell carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| — | NCT05653817 | Jan 2023 → Jan 2025 | cholangiocarcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carrilizumab | “treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg * q21d” NCT05520814 ↗ |
| Modality | Monoclonal antibody | “PD-1 antibody” NCT05919095 ↗ |
| Route | Intravenous | “PD-1 antibody，200mg，D1，intravenous infusion” NCT05919095 ↗ |